The Journal of Allergy and Clinical Immunology: In Practice
Review and Feature ArticleIgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy
Key words
Abbreviations used
Cited by (0)
No funding was received for this work.
Conflicts of interest: M. Humbert reports personal fees from AstraZeneca, Novartis, Roche, Sanofi, and TEVA, during the conduct of the study; and reports grants and personal fees from GSK. J. Bousquet reports personal fees and other from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, and Uriach; and reports other from KYomed-INNOV, outside the submitted work. C. Bachert reports advisory board and presentation fees received from Sanofi, Novartis, Astra-Zeneca, GSK, ALK, Stallergenes, ASIT Biotech, and Actobiotics. O. Palomares received lecture fees from Novartis, Sanofi-Genzyme, AstraZeneca, Amgen, Inmunotek S.L., Allergic Therapeutics, and Stallergenes; participated in advisory boards from Novartis and Sanofi-Genzyme; and received research grants from Novartis, ImmunoTek, and MINECO. P. Pfister, I. Kottakis, and X. Jaumont are employees of Novartis Pharma AG. S. F. Thomsen has been a paid speaker, served on advisory boards, been an investigator, and received research grants from Novartis. N. G. Papadopoulos has received research support from Gerolymatos, Menarini, Nutricia, and Vian; speaker fees from AstraZeneca, Boehringer Ingelheim, HAL, Menarini, MSD, Mylan, Novartis, and Nutricia; participated in advisory boards from ASIT, AZ, Biomay, Chiesi, HAL, Menarini, Mylan, Novartis, Nutricia, and Wockhardt; serves as the president of REG, CAP; is a board member of GA2LEN, ResViNET; and is a committee member of European Academy of Allergy and Clinical Immunology, World Allergy Organization.